FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017666937> ?p ?o ?g. }

• W2017666937 endingPage "103" @default.
• W2017666937 startingPage "99" @default.
• W2017666937 abstract "Although a combination of mifepristone and a prostaglandin is a safe, acceptable alternative to vacuum aspiration for inducing abortion in early pregnancy, the longer period of vaginal bleeding after medical abortion is a disadvantage. The present study investigated whether administration of the combined oral contraceptive pill (COC) or the injection of methotrexate at the time of abortion would shorten the period of vaginal bleeding after medical abortion. After having a medical abortion induced with mifepristone (200 mg) and 0.5 mg gemeprost pessary, 80 women were randomized to four groups of 20 women each; Group A, COC; Group B, control; Group C, 50 mg/m2 methotrexate; and Group D, placebo injection. There was no significant difference in the duration of bleeding between Groups A and B (median 14 and 17 days) or between Groups C and D (18 and 15 days), or in the amount of bleeding (4 days of heavy bleeding in each group). The first period occurred sooner in Group A who took the COC (median/range: 25/15-54 control group versus 32/16-46 days, p < 0.04). The administration of methotrexate was associated with a temporary elevation in liver enzyme concentration in one woman. It is concluded that women who wish to use COC can start immediately after medical abortion. Addition of methotrexate after abortion has no significant beneficial effect on patterns of bleeding and cannot be recommended.The capability of administration of a combined oral contraceptive (OC) or injection of methotrexate at the time of medical abortion to shorten the duration of vaginal bleeding was assessed in a randomized trial conducted in Edinburgh, Scotland, in 1996-97. 80 women seeking pregnancy termination at less than 63 days' gestation were given 200 mg oral mifepristone, followed 48 hours later by 0.5 mg cervagem by vaginal pessary. After the products of conception had passed, women received one of the following four regimens: Group A--an OC (30 mcg ethinyl estradiol and 150 mcg levonorgestrel) to be started immediately after termination; Group B--the same OC, to be started on the first day of the next menstrual period; Group C--50 mg/sq. mm of methotrexate; or Group D--placebo (saline) injection. There was no significant difference between Groups A and B in the median duration of bleeding (14 and 17 days, respectively) or between Groups C and D (18 and 15 days, respectively). Women in all four groups experienced 4 days of heavy bleeding. The first menstrual period occurred after a median of 25 days in Group A compared with 32 days in the other groups. These results indicate that methotrexate administration after medical abortion has no significant beneficial effect on bleeding patterns. Although OCs also failed to control bleeding, their initiation immediately after medical abortion can be considered to ensure rapid restoration of menstruation and provide women with reassurance that they are not pregnant again." @default.
• W2017666937 created "2016-06-24" @default.
• W2017666937 creator A5017820445 @default.
• W2017666937 creator A5022230895 @default.
• W2017666937 creator A5036889785 @default.
• W2017666937 date "1998-08-01" @default.
• W2017666937 modified "2023-10-03" @default.
• W2017666937 title "A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary" @default.
• W2017666937 cites W1970779390 @default.
• W2017666937 cites W1974401340 @default.
• W2017666937 cites W1991445636 @default.
• W2017666937 cites W2012997712 @default.
• W2017666937 cites W2017251100 @default.
• W2017666937 cites W2047572556 @default.
• W2017666937 cites W2054575398 @default.
• W2017666937 cites W2075862388 @default.
• W2017666937 cites W2133425397 @default.
• W2017666937 cites W2155902690 @default.
• W2017666937 cites W2317224967 @default.
• W2017666937 cites W2412683167 @default.
• W2017666937 cites W2414141721 @default.
• W2017666937 doi "https://doi.org/10.1016/s0010-7824(98)00072-9" @default.
• W2017666937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9773264" @default.
• W2017666937 hasPublicationYear "1998" @default.
• W2017666937 type Work @default.
• W2017666937 sameAs 2017666937 @default.
• W2017666937 citedByCount "25" @default.
• W2017666937 countsByYear W20176669372012 @default.
• W2017666937 countsByYear W20176669372013 @default.
• W2017666937 countsByYear W20176669372014 @default.
• W2017666937 countsByYear W20176669372015 @default.
• W2017666937 countsByYear W20176669372020 @default.
• W2017666937 countsByYear W20176669372021 @default.
• W2017666937 countsByYear W20176669372022 @default.
• W2017666937 countsByYear W20176669372023 @default.
• W2017666937 crossrefType "journal-article" @default.
• W2017666937 hasAuthorship W2017666937A5017820445 @default.
• W2017666937 hasAuthorship W2017666937A5022230895 @default.
• W2017666937 hasAuthorship W2017666937A5036889785 @default.
• W2017666937 hasConcept C131872663 @default.
• W2017666937 hasConcept C141071460 @default.
• W2017666937 hasConcept C142724271 @default.
• W2017666937 hasConcept C204787440 @default.
• W2017666937 hasConcept C27081682 @default.
• W2017666937 hasConcept C2776106523 @default.
• W2017666937 hasConcept C2776443887 @default.
• W2017666937 hasConcept C2778642596 @default.
• W2017666937 hasConcept C2778826759 @default.
• W2017666937 hasConcept C2779199973 @default.
• W2017666937 hasConcept C2779234561 @default.
• W2017666937 hasConcept C2779560327 @default.
• W2017666937 hasConcept C2780218171 @default.
• W2017666937 hasConcept C2781059491 @default.
• W2017666937 hasConcept C29456083 @default.
• W2017666937 hasConcept C54355233 @default.
• W2017666937 hasConcept C71924100 @default.
• W2017666937 hasConcept C86803240 @default.
• W2017666937 hasConceptScore W2017666937C131872663 @default.
• W2017666937 hasConceptScore W2017666937C141071460 @default.
• W2017666937 hasConceptScore W2017666937C142724271 @default.
• W2017666937 hasConceptScore W2017666937C204787440 @default.
• W2017666937 hasConceptScore W2017666937C27081682 @default.
• W2017666937 hasConceptScore W2017666937C2776106523 @default.
• W2017666937 hasConceptScore W2017666937C2776443887 @default.
• W2017666937 hasConceptScore W2017666937C2778642596 @default.
• W2017666937 hasConceptScore W2017666937C2778826759 @default.
• W2017666937 hasConceptScore W2017666937C2779199973 @default.
• W2017666937 hasConceptScore W2017666937C2779234561 @default.
• W2017666937 hasConceptScore W2017666937C2779560327 @default.
• W2017666937 hasConceptScore W2017666937C2780218171 @default.
• W2017666937 hasConceptScore W2017666937C2781059491 @default.
• W2017666937 hasConceptScore W2017666937C29456083 @default.
• W2017666937 hasConceptScore W2017666937C54355233 @default.
• W2017666937 hasConceptScore W2017666937C71924100 @default.
• W2017666937 hasConceptScore W2017666937C86803240 @default.
• W2017666937 hasIssue "2" @default.
• W2017666937 hasLocation W20176669371 @default.
• W2017666937 hasLocation W20176669372 @default.
• W2017666937 hasOpenAccess W2017666937 @default.
• W2017666937 hasPrimaryLocation W20176669371 @default.
• W2017666937 hasRelatedWork W1602576566 @default.
• W2017666937 hasRelatedWork W2004394272 @default.
• W2017666937 hasRelatedWork W2016603468 @default.
• W2017666937 hasRelatedWork W2029521764 @default.
• W2017666937 hasRelatedWork W2362889847 @default.
• W2017666937 hasRelatedWork W2382213285 @default.
• W2017666937 hasRelatedWork W2563196148 @default.
• W2017666937 hasRelatedWork W2957695845 @default.
• W2017666937 hasRelatedWork W3013810766 @default.
• W2017666937 hasRelatedWork W4245803215 @default.
• W2017666937 hasVolume "58" @default.
• W2017666937 isParatext "false" @default.
• W2017666937 isRetracted "false" @default.
• W2017666937 magId "2017666937" @default.
• W2017666937 workType "article" @default.